Edesa Biotech to Showcase at Barclays Global Healthcare Conference

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, announced its participation in the upcoming Barclays 26th Annual Global Healthcare Conference in Miami, Florida, from March 12 to March 14, 2024. The company, known for its focus on developing therapeutics for immuno-inflammatory diseases, looks forward to engaging with attendees and potential investors during the event. Scheduled meetings can be arranged through the conference organizers or directly via the company’s contact email.

Edesa Biotech's pipeline includes several promising drug candidates. Its lead product, EB05 (paridiprubart), is currently in a Phase 3 study targeting Acute Respiratory Distress Syndrome (ARDS). They are also preparing for a Phase 2 study of paridiprubart for pulmonary fibrosis. Additionally, regulatory approval has been granted for a Phase 2 trial of EB06 as a treatment for vitiligo. Moreover, Edesa is developing an sPLA2 inhibitor, EB01, aimed at treating chronic Allergic Contact Dermatitis (ACD).